You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《半新股》3D MEDICINES-B(01244.HK)續升近17%再破頂 上市一個月累漲1.2倍
阿思達克 01-16 15:19
半新股3D MEDICINES-B(01244.HK)四連升,今日(16日)高開近1.3%,報48.5元後,升幅擴大,屆下午約3時,升至56元即市高位,再創上市新高。現報56元,升16.9%,成交36.8萬股,涉資1,941.31萬元。以現價較上月中旬上市價24.98元計,上月約一個月累升1.2倍。 公司剛公布,3D185被美國食品藥品監督管理局(FDA)授予孤兒藥資格認定,用於治療胃癌和胃食管連接處癌。這是3D185的第二個孤兒藥資格認定。 3D Medicines是一家成立於2014年生物醫藥公司,其致力於為癌症患者,尤其是那些需要長期治療患者研發腫瘤藥物。是次在港上市共發售1,635萬股,並已引入包括徐州經開區(香港)、Harvest、TradArt Investment SP及Mobilewise四名基石投資者,合共認購939.15萬股;10%公開發售獲近5倍超購,認購一手中籤率25%;股份以招股範圍(22.96至26.24元)中間以上範圍定價,料集資淨額約2.51億元,主要用作產品和候選藥物研發、監管備案及商業化等。上市聯席保薦人分別中金及中信建投國際。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account